Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …

Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL1 fusion
gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic …

Chemotherapy and molecularly targeted approaches represent two very different modes of
cancer treatment and each is associated with unique benefits and limitations. Both types of …

Abstract Src homology region 2 (SH2) domain–containing phosphatase 1 (SHP-1, also
known as PTPN6) is a nonreceptor protein tyrosine phosphatase that acts as a negative …

Purpose: Here, we aim to investigate the molecular mechanism of regorafenib and verify the
potential druggable target for the treatment of hepatocellular carcinoma (HCC) …

Background Tumor-suppressor genes are inactivated by methylation in several cancers
including acute myeloid leukemia (AML). Src homology-2 (SH2)-containing protein-tyrosine …

Chronic myeloid leukemia (CML) is a hematologic disorder characterized by the oncogene
BCR-ABL1, which encodes an oncoprotein with tyrosine kinase activity. Imatinib, a BCR …

Chronic myeloid leukemia (CML) is initially driven by the bcr–abl fusion oncoprotein. The
identification of bcr–abl led to the discovery and rapid translation into the clinic of bcr–abl …

Introduction Signal transducers and activators of transcription 3 (STAT3) signaling is
constitutively activated in various cancers including breast cancer and has emerged as a …